Portable dialysis machine maker Quanta lands $245M to boost U.S. reach
Summary
The proceeds will also scale up the U.K.-based company’s operations internationally, with a special focus on boosting its U.S. manufacturing, sales and customer service divisions—in addition to setting the stage for a new clinical trial aimed at garnering an FDA green light for at-home use of its portable dialysis device. Quanta’s SC+ hemodialysis machine is small enough to fit on top of a cart or tabletop and is currently cleared for use by healthcare professionals in hospitals and skilled nursing facilities. The smaller machine aims to provide the same level of treatment as its larger counterparts, with a modular, cartridge-based approach to offering high-flow dialysis, such as the typical thrice-a-week appointments as well as gentler procedures given over a longer timespan. “For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care.” The company’s series D financing was led by Glenview Capital and co-led by Novo Holdings, with additional backing from BlackRock, Eldridge, Sands Capital, Millennium Management, Monashee Investment Management, Puhua Capital, Segulah Medical, Ancora, Wellington Partners, btov, Seroba Life Sciences and The Grands, plus integrated delivery network Orlando Health. Its portable Tablo machine has been cleared for home use and has also been deployed to New York City-area hospitals as part of an emergency response to COVID-19.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
